642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

Benefit VA Assessing the benefit of venetoclax addition in veterans with CLL SLL responding to BTK inhibitor therapy

CaDAnCe 304 a phase 3 open label randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB 16673 compared with pirtobrutinib in patients with relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma

The efficacy and safety of pirtobrutinib in patients with CLL SLL A phase 2 dose optimization trial in progress

Real world study on the impact of continuous treatment dose interruption or reduction of COVALENT BTK inhibitors on efficacy A 7 year follow up in chronic lymphocytic leukemia specialized clinics at tertiary hospitals in shanghai China

Long progression free survival with venetoclax consolidation in patients with high risk chronic lymphocytic leukemia treated with ibrutinib

Venetoclax initiation monitoring and interventions after acalabrutinib lead in for chronic lymphocytic leukemia

Efficacy of pirtobrutinib monotherapy in treatment naïve chronic lymphocytic leukemia A Bayesian network meta analysis of randomized controlled trials

Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed refractory hairy cell leukemia

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia CLL treated with zanubrutinib A post hoc analysis of two phase 3 studies SEQUOIA and ALPINE

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and or cardiovascular adverse events

Mesutoclax ICP 248 monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia small lymphocytic lymphoma CLL SLL

A Phase II multicenter study of minimal residual disease guided time limited acalabrutinib obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Clinical cytogenetic and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Pirtobrutinib versus usual care for patients with richter transformation of chronic lymphocytic leukemia Inverse probability of treatment weighting based analysis of BRUIN trial and mayo observational cohort

First line ibrutinib venetoclax shows benefit across genomic subgroups in patients with chronic lymphocytic leukemia CLL Results from Phase 2 captivate study and Phase 3 glow study

Pirtobrutinib outcomes in second line 2L chronic lymphocytic leukemia small lymphocytic lymphoma CLL SLL after first line 1L cBTKi therapy A pooled analysis from the BRUIN LOXO BTK 18001 and BRUIN CLL 321 studies

Zanubrutinib venetoclax for treatment naive chronic lymphocytic leukemia small lymphocytic lymphoma CLL SLL including patients with del 17p and or TP53 mutation and unmutated immunoglobulin heavy chain variable status 3 year results from SEQUOIA arm D

Progression of disease within 36 months POD36 of starting first line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia CLL

Primary analysis of a multicenter open label phase 2 study of sonrotoclax BGB 11417 monotherapy in patients with relapsed refractory R R chronic lymphocytic leukemia or small lymphocytic lymphoma CLL SLL

Real world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities Interim analysis of the multicenter study conducted by eric

Survival differences of patients with treatment naive CLL between the chemoimmunotherapy and BTKi eras An eric study

Zanubrutinib is well tolerated and effective in acalabrutinib intolerant patients with B cell malignancies A long term follow up

Acalabrutinib versus venetoclax plus obinutuzumab in treatment naive chronic lymphocytic leukemia A real world propensity score matched study